228 related articles for article (PubMed ID: 36181605)
1. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
van Ommen-Nijhof A; Jacobse JN; Steggink LC; Lefrandt JD; Gietema JA; van Leeuwen FE; Schaapveld M; Sonke GS
Breast Cancer Res Treat; 2022 Dec; 196(3):591-602. PubMed ID: 36181605
[TBL] [Abstract][Full Text] [Related]
2. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Disease After Aromatase Inhibitor Use.
Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
[TBL] [Abstract][Full Text] [Related]
4. Treatment with aromatase inhibitors and markers of cardiovascular disease.
Blondeaux E; Musio D; Bruzzi P; Lambertini M; Gazzola V; Poggio F; Vecchio S; Levaggi A; D'Alonzo A; Perfumo MC; Bighin C; Giraudi S; Palombo D; Del Mastro L
Breast Cancer Res Treat; 2016 Nov; 160(2):261-267. PubMed ID: 27663435
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
8. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
10. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
12. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.
Seo DH; Cho Y; Lee S; Park S; Kim SI; Park BW; Rhee Y
Korean J Intern Med; 2019 May; 34(3):579-587. PubMed ID: 28838227
[TBL] [Abstract][Full Text] [Related]
14. Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk.
Sund M; Garmo H; Andersson A; Margolin S; Ahlgren J; Valachis A
Breast Cancer Res Treat; 2023 Apr; 198(2):361-368. PubMed ID: 36773184
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
19. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors.
Su HI; Sammel MD; Springer E; Freeman EW; DeMichele A; Mao JJ
Breast Cancer Res Treat; 2010 Nov; 124(1):205-11. PubMed ID: 20182796
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]